Thomas Schluep

Thomas Schluep is the current VP of Program Management at Arrowhead Pharmaceuticals. Thomas has over 15 years of experience in the field of pharmaceuticals, with a focus on drug delivery and development.

Thomas started their career at Insert Therapeutics, where they were responsible for the planning, management, and oversight of the company's drug discovery and development programs. During their time there, they successfully brought IT-101, the company's lead anticancer compound, from bench to clinic in less than 2 years.

In 2008, they left Insert Therapeutics to join Calando Pharmaceuticals as their CSO. At Calando, they oversaw the company's research and development activities, including their clinical siRNA candidate (CALAA-01), which was the first targeted and fully formulated siRNA therapeutic to enter the clinic. In June 2009, they helped negotiate a deal that saw Calando's IT-101 and Cyclosert drug delivery platform being out-licensed for > $35 million.

Thomas joined Arrowhead Pharmaceuticals in July 2009 and has since been overseeing the company's program management activities. Under their leadership, Arrowhead has continued to grow and develop new therapeutics that are making a difference in the lives of patients around the world.

Thomas Schluep received a Sc.D. in Process Engineering from ETH Zürich and a Diploma in Biotechnology from ETH Zürich.

They are on a team with Randy Steiner - VP, Regulatory Affairs, Tracie Oliver - Chief Commercial Officer, and Jane Davidson - VP, Human Resources. Their manager is Christopher Anzalone, President & CEO.